Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.

Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY.

Neoplasia. 2017 Oct;19(10):848-855. doi: 10.1016/j.neo.2017.08.004. Epub 2017 Sep 15.

2.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS.

Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.

3.

A STING-activating nanovaccine for cancer immunotherapy.

Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, Du M, Huang G, Wang C, Chen X, Porembka MR, Lea J, Frankel AE, Fu YX, Chen ZJ, Gao J.

Nat Nanotechnol. 2017 Jul;12(7):648-654. doi: 10.1038/nnano.2017.52. Epub 2017 Apr 24.

4.

Academic Cancer Center Phase I Program Development.

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP.

Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17.

5.

Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.

Frankel AE, Eskiocak U, Gill JG, Yuan S, Ramesh V, Froehlich TW, Ahn C, Morrison SJ.

Neoplasia. 2017 Apr;19(4):255-260. doi: 10.1016/j.neo.2017.01.010. Epub 2017 Mar 6.

6.

Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells.

Thorburn J, Staskiewicz L, Goodall ML, Dimberg L, Frankel AE, Ford HL, Thorburn A.

Mol Pharmacol. 2017 Jan;91(1):58-64. Epub 2016 Nov 9.

7.

Blastic plasmacytoid dendritic cell neoplasm with t(11;19)(q23;p13.3);KMT2A(MLL) rearranged: a diagnostic challenge.

Gehlbach D, Koduru P, John G, Fuda F, Frankel AE, Chen W.

Br J Haematol. 2017 Jan;176(1):8. doi: 10.1111/bjh.14389. Epub 2016 Oct 24. No abstract available.

PMID:
27774582
8.

Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.

Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Frankel AE, Johnson TM, DeBerardinis RJ, Morrison SJ.

Nat Commun. 2016 Sep 29;7:13080. doi: 10.1038/ncomms13080. No abstract available.

9.

Developing EZH2-Targeted Therapy for Lung Cancer.

Frankel AE, Liu X, Minna JD.

Cancer Discov. 2016 Sep;6(9):949-52. doi: 10.1158/2159-8290.CD-16-0800.

10.

Discharging dynamics in an electrolytic cell.

Feicht SE, Frankel AE, Khair AS.

Phys Rev E. 2016 Jul;94(1-1):012601. doi: 10.1103/PhysRevE.94.012601. Epub 2016 Jul 5.

PMID:
27575173
11.

Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).

Bekdash A, Darwish M, Timsah Z, Kassab E, Ghanem H, Najjar V, Ghosn M, Nasser S, El-Hajj H, Bazerbachi A, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ.

Transl Oncol. 2015 Oct;8(5):347-57. doi: 10.1016/j.tranon.2015.07.001.

12.

Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency.

Burrage LC, Sun Q, Elsea SH, Jiang MM, Nagamani SC, Frankel AE, Stone E, Alters SE, Johnson DE, Rowlinson SW, Georgiou G; Members of Urea Cycle Disorders Consortium, Lee BH.

Hum Mol Genet. 2015 Nov 15;24(22):6417-27. doi: 10.1093/hmg/ddv352. Epub 2015 Sep 10.

13.

Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.

Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM.

Haematologica. 2015 Jun;100(6):794-800. doi: 10.3324/haematol.2015.123711. Epub 2015 Mar 20.

14.

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.

Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA.

Clin Cancer Res. 2015 Mar 15;21(6):1267-72. doi: 10.1158/1078-0432.CCR-14-2877.

15.

Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells.

Khoury O, Ghazale N, Stone E, El-Sibai M, Frankel AE, Abi-Habib RJ.

J Neurooncol. 2015 Mar;122(1):75-85. doi: 10.1007/s11060-014-1698-5. Epub 2015 Jan 8.

PMID:
25567351
16.

Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.

Rakheja D, Fuda F, Vandergriff T, Boriack R, Medeiros BC, Frankel AE, Chen W.

Hum Pathol. 2015 Feb;46(2):322-6. doi: 10.1016/j.humpath.2014.10.013. Epub 2014 Nov 4.

PMID:
25481493
17.

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F.

Haematologica. 2015 Feb;100(2):223-30. doi: 10.3324/haematol.2014.111740. Epub 2014 Nov 7.

18.

In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts.

Agrawal V, Woo JH, Mauldin JP, Stone EM, Meininger CJ, Jo C, Kleypas K, Frenkel EP, Frankel AE.

Melanoma Res. 2014 Dec;24(6):556-67. doi: 10.1097/CMR.0000000000000119.

PMID:
25304236
19.

Dynamics of a self-diffusiophoretic particle in shear flow.

Frankel AE, Khair AS.

Phys Rev E Stat Nonlin Soft Matter Phys. 2014 Jul;90(1):013030. Epub 2014 Jul 31.

PMID:
25122392
20.

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.

Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M.

Br J Haematol. 2014 Sep;166(6):862-74. doi: 10.1111/bjh.12978. Epub 2014 Jun 19.

21.

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E.

Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23.

22.

Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity.

Frankel AE.

Clin Pharmacol. 2013 Nov 26;5(Suppl 1):1-3. doi: 10.2147/CPAA.S55613. eCollection 2013. No abstract available.

23.

Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells.

Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE, Abi-Habib RJ.

Leuk Res. 2013 Nov;37(11):1565-71. doi: 10.1016/j.leukres.2013.08.007. Epub 2013 Aug 16.

PMID:
24018014
24.

Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.

Kassab E, Darwish M, Timsah Z, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ.

Transl Oncol. 2013 Feb;6(1):25-32. Epub 2013 Feb 1.

25.

Arginine deprivation therapy for malignant melanoma.

Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB.

Clin Pharmacol. 2013;5:11-9. doi: 10.2147/CPAA.S37350. Epub 2012 Dec 27.

26.

Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.

Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW.

Clin Cancer Res. 2013 Jan 1;19(1):148-57. doi: 10.1158/1078-0432.CCR-12-1258. Epub 2012 Nov 21.

27.
28.

Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.

Agrawal V, Woo JH, Borthakur G, Kantarjian H, Frankel AE.

Protein Pept Lett. 2013 Apr;20(4):392-402. Review.

PMID:
23016580
29.

Toll-like receptor 4 knockout protects against anthrax lethal toxin-induced cardiac contractile dysfunction: role of autophagy.

Kandadi MR, Frankel AE, Ren J.

Br J Pharmacol. 2012 Oct;167(3):612-26. doi: 10.1111/j.1476-5381.2012.02040.x.

30.

Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics.

Kuo SR, Tahir SA, Park S, Thompson TC, Coffield S, Frankel AE, Liu JS.

Hybridoma (Larchmt). 2012 Apr;31(2):77-86. doi: 10.1089/hyb.2011.0100.

31.

Recombinant human arginase toxicity in mice is reduced by citrulline supplementation.

Mauldin JP, Zeinali I, Kleypas K, Woo JH, Blackwood RS, Jo CH, Stone EM, Georgiou G, Frankel AE.

Transl Oncol. 2012 Feb;5(1):26-31. Epub 2012 Feb 1.

32.

Targeting methionine auxotrophy in cancer: discovery & exploration.

Agrawal V, Alpini SE, Stone EM, Frenkel EP, Frankel AE.

Expert Opin Biol Ther. 2012 Jan;12(1):53-61. doi: 10.1517/14712598.2012.636349. Epub 2011 Nov 5. Review.

PMID:
22171665
33.

TEM8 targeted cancer therapy.

Frankel AE, Carter C, Kuo SR, Woo JH, Mauldin J, Liu JS.

Anticancer Agents Med Chem. 2011 Dec;11(10):983-92.

PMID:
22023048
34.

Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells.

Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, Frankel AE.

Anticancer Drugs. 2012 Jan;23(1):51-64. doi: 10.1097/CAD.0b013e32834ae42b.

PMID:
21955999
35.

The cell surface structure of tumor endothelial marker 8 (TEM8) is regulated by the actin cytoskeleton.

Yang MY, Chaudhary A, Seaman S, Dunty J, Stevens J, Elzarrad MK, Frankel AE, St Croix B.

Biochim Biophys Acta. 2011 Jan;1813(1):39-49. doi: 10.1016/j.bbamcr.2010.11.013. Epub 2010 Dec 1.

36.

1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancer.

Vanderlaag K, Su Y, Frankel AE, Burghardt RC, Barhoumi R, Chadalapaka G, Jutooru I, Safe S.

BMC Cancer. 2010 Dec 3;10:669. doi: 10.1186/1471-2407-10-669.

37.

Computational and experimental investigations of mono-septanoside binding by Concanavalin A: correlation of ligand stereochemistry to enthalpies of binding.

Duff MR Jr, Fyvie WS, Markad SD, Frankel AE, Kumar CV, Gascón JA, Peczuh MW.

Org Biomol Chem. 2011 Jan 7;9(1):154-64. doi: 10.1039/c0ob00425a. Epub 2010 Nov 18.

PMID:
21085738
38.

Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanism.

Kandadi MR, Hua Y, Ma H, Li Q, Kuo SR, Frankel AE, Ren J.

PLoS One. 2010 Oct 13;5(10):e13335. doi: 10.1371/journal.pone.0013335.

39.

14G2a anti-GD2 crossreactivity with the CD166 antigen.

Agrawal V, Frankel AE.

J Immunother. 2010 Nov-Dec;33(9):1014-5. doi: 10.1097/CJI.0b013e3181f3bf36. No abstract available.

PMID:
20948433
40.

Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials.

Woo JH, Lee YJ, Neville DM, Frankel AE.

Methods Mol Biol. 2010;651:157-75. doi: 10.1007/978-1-60761-786-0_10.

PMID:
20686966
41.

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Vallera DA, Oh S, Chen H, Shu Y, Frankel AE.

Mol Cancer Ther. 2010 Jun;9(6):1872-83. doi: 10.1158/1535-7163.MCT-10-0203. Epub 2010 Jun 8.

42.
43.

Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.

Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS, Mitchell IC, Nwariaku F, Frankel AE.

Mol Cancer Ther. 2010 Jan;9(1):190-201. doi: 10.1158/1535-7163.MCT-09-0694. Epub 2010 Jan 6.

44.

Antibody internalization after cell surface antigen binding is critical for immunotoxin development.

Kuo SR, Alfano RW, Frankel AE, Liu JS.

Bioconjug Chem. 2009 Oct 21;20(10):1975-82. doi: 10.1021/bc900333j. Epub 2009 Sep 28.

PMID:
19785403
45.

Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials.

Su Y, Li SY, Ghosh S, Ortiz J, Hogge DE, Frankel AE.

Biologicals. 2010 Jan;38(1):144-9. doi: 10.1016/j.biologicals.2009.08.016. Epub 2009 Sep 23.

PMID:
19783458
46.

EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.

Horita H, Thorburn J, Frankel AE, Thorburn A.

J Neurooncol. 2009 Nov;95(2):175-184. doi: 10.1007/s11060-009-9914-4. Epub 2009 May 17.

47.

Bispecific immunotoxins.

Frankel AE, Woo JH.

Leuk Res. 2009 Sep;33(9):1173-4. doi: 10.1016/j.leukres.2009.03.037. Epub 2009 Apr 29. No abstract available.

PMID:
19406472
48.

Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.

Liu S, Bugge TH, Frankel AE, Leppla SH.

Methods Mol Biol. 2009;539:175-90. doi: 10.1007/978-1-60327-003-8_10.

49.

Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.

Alfano RW, Leppla SH, Liu S, Bugge TH, Meininger CJ, Lairmore TC, Mulne AF, Davis SH, Duesbery NS, Frankel AE.

Mol Cancer Res. 2009 Apr;7(4):452-61. doi: 10.1158/1541-7786.MCR-08-0451.

50.

Pathophysiology of anthrax.

Frankel AE, Kuo SR, Dostal D, Watson L, Duesbery NS, Cheng CP, Cheng HJ, Leppla SH.

Front Biosci (Landmark Ed). 2009 Jan 1;14:4516-24. Review.

Supplemental Content

Loading ...
Support Center